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Introduction 
 
Type 1 diabetes is a multifactorial disease resulting from a complex interplay between 
host genetics, the immune system and the environment, that culminates in the 
destruction of insulin-producing beta cells. The incidence of type 1 diabetes is 
increasing at an alarming rate, especially in children under the age of 5 [1-3]. Genetic 
predisposition, although clearly important, cannot explain this rise and so it has been 
proposed that changes in the ‘environment’ and/or changes in ‘how we respond to our 
environment’ must contribute to this rising incidence. In order to gain an improved 
understanding of the factors influencing the disease process, it is important, firstly, to 
focus on the organ at the centre of the illness; the pancreas. This review summarises 
our knowledge of the pathology of the endocrine pancreas in human type 1 diabetes 
and, in particular, explores the progression of this understanding over the past 25 
years. 
 
What was known 25 years ago? 
 
While there had been numerous studies of the autopsy pancreas in young persons with 
diabetes before, the foundations of this subject were laid by the seminal article of 
Willy Gepts in 1965 [4]. Gepts noted the presence of insulitis (a predominantly 
lymphocytic inflammatory infiltrate of islets) in 15 of 22 (68%) autopsies of persons, 
under the age of 30, dying within 6 months of a diagnosis of diabetes [4]. These 
findings were later confirmed in a larger collection of UK samples, where 47 out of 
60 (78%) young patients (<20 years) with recent-onset type 1 diabetes were found to 
have evidence of insulitis [5]. Prior to the development of immunohistochemistry 
Gepts also noted that the pancreas in persons who had had the disease for many years 
was characterized by an almost complete lack of insulin secreting beta cells. From 
these observations he raised two hypotheses: the islet inflammation could be 
secondary to a viral infection of beta cells or it could represent an immunologically 
driven process, akin to autoimmune thyroiditis. 
 
Support for both these theories followed. Gamble, Taylor and Cumming [6] found 
that patients with recently diagnosed type 1 diabetes were more likely than controls to 
have antibodies to Coxsackie viruses, and Coxsackie B4 virus was cultured from the 
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pancreas of a 10 year old boy who had died at clinical presentation of type 1 diabetes 
[7]. This case may have been exceptional in that the virus was also cultured from the 
brain of the child, raising the possibility of an incidental viraemia. Many attempts 
have since been made to culture viruses from the pancreas of recent onset diabetic 
patients, largely without success.  
 
In 1974 two separate groups reported the presence of islet cell autoantibodies in 
patients with type 1 diabetes [8-10], leading to the disease being later classified as an 
organ specific autoimmune disease with the insulin secreting beta cells as the target. 
 
Following the advent of immunohistochemistry being applied to paraffin embedded 
tissue, it was shown that within the pancreas of children dying at clinical presentation 
of their disease that the majority of islets (70%) were small and had no beta cells [11]. 
They had a normal complement of glucagon secreting alpha cells, somatostatin 
secreting delta cells and pancreatic polypeptide secreting PP cells and were termed 
insulin deficient islets (IDI). The remainder of the islets had residual beta cells and 
were called insulin containing islets (ICI). Insulitis affected 18% of ICI but only 1% 
of IDI. This was the first evidence that insulitis affected ICI primarily and lent support 
to the idea that it represented an immunologically driven destruction of beta cells [11]. 
Importantly the lobular distribution of the disease was also noted (Figure 1), where a 
seemingly unaffected lobe, or one where ICIs with insulitis could be observed, were 
frequently surrounded by lobes containing only IDIs. 
 
It also became clear that the pancreas at clinical presentation could be studied to look 
at the time course of events within the organ. Insulin deficient islets were islets where 
beta cells had been destroyed in the past; ICI with insulitis were islets where beta cells 
were being destroyed at the time of the death of the patient, and ICI with no insulitis 
were islets where the beta cells were yet to be attacked and destroyed. Gepts [4] had 
suggested that the destruction of beta cells must happen over years and support for 
this was the finding of insulitis affecting ICI up to 6 years after clinical onset of 
diabetes [5]. 
 
Prior to the development of antigen retrieval, many antigens could only be studied by 
immunohistochemistry on tissues that had not been fixed in formalin. 
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Characterization of the inflammatory cell infiltrate in insulitis for many years relied 
on one report where fresh frozen pancreas had been collected at the time of death 
from a child with recent onset diabetes [12]. The majority of the inflammatory cells 
were T lymphocytes and the majority of them expressed CD8, suggesting that they 
were likely to be cytotoxic T cells. Macrophages were not abundant.  
 
Cytotoxic CD8 T cells can recognize an antigen when it is presented to them bound to 
cellular class I major histocompatability complex (MHC) molecules. This 
presentation is enhanced if there is increased expression of class I MHC. Bottazzo et 
al [12] noticed that endocrine cells in some islets in the single pancreas that they 
studied hyperexpressed class I MHC but they did not fully characterize this 
phenomenon and did not describe which cells were affected. This feature was later 
elucidated in a study of 23 pancreases from persons dying of recent onset type 1 
diabetes [13]. Hyper expression of class I MHC was found in all pancreases where 
there were residual beta cells (an example is shown in Fig. 2). It affected 92% of ICI 
but only 1% of IDI. The phenomenon was not seen in 95 control pancreases, which 
included normal and diseased pancreases (graft versus host disease, Coxsackie viral 
infection, type 2 diabetes, chronic pancreatitis, cystic fibrosis). It was thus as much a 
characteristic of type 1 diabetes as insulitis and insulin deficient islets. 
 
Within affected islets all endocrine cells (alpha, beta, delta and PP) hyperexpressed 
class I MHC. Whilst islets complicated by insulitis uniformly hyperexpressed class I 
MHC if they had residual beta cells, many otherwise normal ICI, with no evidence of 
insulitis even on serial sectioning, also displayed this phenomenon [13]. This 
suggested that hyper-expression of class I MHC must precede insulitis in the disease 
process. 
 
It was hypothesized that if alpha, delta and PP cells hyperexpressed class I MHC 
when they were adjacent to beta cells in ICI, but ceased to do this when they were 
physically divorced from beta cells in IDI, following the destruction of beta cells in 
the insulitis process, then perhaps the islet beta cells were releasing some paracrine 
substance capable of causing hyper expression of class I MHC on adjacent islet 
endocrine cells. Candidates for this role included type 1 interferons (interferon-alpha 
(IFNα) and beta) and interferon-gamma, as they had been shown to cause hyper 
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expression of class I MHC on islet endocrine cells in vitro) [14]. Interferon-gamma is 
released only by T lymphocytes so attention was focused on type 1 interferons. 
 
The possibility that the secretion of IFNα by islet beta cells plays a role in the 
induction of class I MHC hyper expression in ICI was then assessed [15]. In a study 
of 34 patients with type 1 diabetes, insulin containing beta cells were shown to exhibit 
IFNα in 93% of islets which hyperexpressed class I MHC but in only 0.4% of islets 
which did not show this phenomenon. Among 80 control pancreases with a variety of 
diseases, only in 4 neonates affected by Coxsackie B viral infection were beta cells 
found to express IFNα [15]. 
 
The following sequence of events leading to diabetes was then hypothesized. In a 
given individual, pancreatic beta cells might harbour a non-cytopathic chronic viral 
infection to which the body could react in a number of ways, perhaps partly 
determined by their genetic susceptibility to diabetes. If there was no immune 
response then no disease might result. By contrast if the infected cells expressed 
interferon-alpha (as part of an innate immune response to the double stranded RNA of 
the virus) this would result in hyper expression of class I MHC by the endocrine cells 
of the islet. Such expression might provoke loss of immune tolerance and infiltration 
of affected islets by inflammatory cells. Even a very weak autoimmune response to 
beta cell antigens in the context of class I MHC hyper expression would eventually 
(over years) lead to their destruction and the development of clinical diabetes (Figure 
1; Foulis Oakley Lecture 1987 [16])   
 
Insulitis: 25 years on…. 
 
Since the seminal contributions of Gepts, the concept that type 1 diabetes arises from 
a process of immune-mediated destruction of pancreatic beta-cells has continued to 
develop and expand. However, an important question still remains – how strong is the 
evidence that insulitis is a characteristic feature of human type 1 diabetes? Certainly, 
Gepts was persuaded of the concept when he noted in 1981 that insulitis is “a 
common finding in the pancreas of recent onset juvenile diabetic subjects”. 
Unfortunately, however, firm corroboration has been achieved only slowly, to the 
extent that In’t Veld, in reviewing the weight of evidence, has recently defined 
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insulitis in the human pancreas as an “elusive lesion” [17]. In particular, he noted that 
the number of recorded cases of insulitis worldwide has hardly increased over the last 
25 years such that the total currently stands at only about 200. As a result, the 
essential features of the lesion are still debated.  
 
An important issue arising from the study of insulitis is that the number of infiltrating 
cells in any given islet is relatively few [18]. This stands in marked contrast to the 
situation in the NOD mouse (a model of spontaneous autoimmune diabetes) where, 
typically, inflamed islets are surrounded by an army of infiltrating cells which initially 
adopt a peripheral configuration before migrating deep within the islet structure to 
achieve close-contact with the endocrine cells [19]. In our experience, the equivalent 
situation is rare in human tissue. Rather, in the case of human islets, the inflammatory 
infiltrate often numbers only a few cells in any given islet cross-section and the 
majority of these reside around the islet perimeter (Figure 3: Peri-insulitis and/or focal 
insulitis). Very few immune cells actually cross the threshold to enter the margins of 
the islet structure and come into close contact with the endocrine cells. Thus, the 
process of beta-cell destruction appears rather inefficient and this may account for the 
relatively protracted time course preceding the onset of clinical symptoms in many 
patients.  
 
This, in turn, prompts a further critical issue in that it becomes extremely important to 
establish a firm definition of “insulitis” in human pancreas since it is probable that 
small numbers of immune cells are likely to be present within even “normal” (non-
inflamed) islets. Distinguishing the “normal” from the “inflamed” situation then 
becomes a key priority. To help address this issue, a meeting was held in Florida in 
early 2013, at which a number of investigators who have studied human insulitis, 
were present. Collectively, these workers developed a consensus statement to define 
insulitis: In a pancreas containing insulin deficient islets the lesion should only be 
confirmed if at least 3 individual islet sections contain a minimum of 15 lymphocytes 
(located either at the islet periphery and/or within the islet structure) [20]. This figure 
was chosen as it represents at least double the number of such cells found in the islets 
of control tissue (after extensive analysis of several thousand islets across multiple 
pancreases). This consensus definition represents the state-of-the-art in 2013 and 
provides an important context in which the process can be studied [20].  
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Definition of the numbers of infiltrating immune cells within islets represents an 
important step forward in the study of insulitis but it is not, itself, a fully informative 
statistic. This is because the nature of the infiltrate will determine the cytokine profile 
within the islet milieu and therefore, a second important objective is to establish the 
phenotypes of the various immune cells that may be present. We undertook a 
comprehensive analysis of the immune cell phenotypes present within insulitic lesions 
in 29 separate individuals who had died shortly after being diagnosed with type 1 
diabetes[18]. This revealed that both the absolute number and the profile of immune 
cells present in inflamed islets is variable. Indeed, immune cells appear to enter and 
leave islets as the process progresses, such that the profile of immune cell subsets 
differs according to the extent of beta-cell loss. Despite this, some clear trends 
emerged; notably that CD8+ T-cells comprise the majority of the population at all 
stages of insulitis. By contrast, CD4+ T-cells are relatively under-represented in the 
immune cell population [18].  
 
It is self-evident that the dynamics of immune cell infiltration cannot be fully assessed 
in fixed tissue preparations taken at a single time point but, nevertheless, it is still 
possible to make reasonable inferences by studying islets at varying stages of beta cell 
destruction. When the data were processed in this way, a dynamic model emerged in 
which CD8+ T-cells featured as the most prominent cells leading the islet attack and 
they were accompanied by reduced proportions of CD4+ T-cells and CD68+ 
macrophages. Importantly, the CD8+ cells increased in number as beta-cell 
destruction proceeded, implying that they play a primary role in mediating this 
demise. By contrast, CD4+ and CD68+ cell numbers remained much more constant. 
More surprisingly, a further lymphocyte subset was found to mirror the profile of 
CD8+ T-cells, in that CD20+ B-cells also increased in numbers markedly, to achieve 
a status as the second most prevalent cell type in many of the patients[18]. The 
functional activity of these cells remains to be determined but they do not appear to be 
antibody-secreting plasma cells. By analogy with the situation in NOD mouse (which, 
as indicated above, provides an exaggerated representation of human insulitis) it is 
possible that these B-cells are somehow trophic for the CD8+ T-cells, allowing them 
to reach their full cytotoxic potential [21]. However, it has also become clear that 
CD20+ cells are not absolutely required for CD8+ cells to promote beta-cell loss 
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since, in a more recent study reported in abstract form, a subset of patients was 
identified whose islets are not infiltrated by significant numbers of CD20+ cells but 
who, nevertheless, progressed to clinical type 1 diabetes [22].  Conceivably, then, the 
CD20+ cells may play a facilitating rather than a primary role in beta-cell 
cytotoxicity. 
 
In an earlier study using samples recovered from a different (and much smaller) group 
of patients, Dotta and colleagues had identified the presence of NK cells within some 
insulitic lesions[23]. This suggests that such cells might also play a role in mediating 
beta-cell loss under some circumstances, although in our series of patients we were 
unable to detect significant infiltration of NK cells [18].  
 
Taken together, the weight of recent evidence supports the view that CD8+ T-cells are 
likely to be primarily responsible for driving beta-cell loss and this conclusion is 
supported by a more a recent development which represents an important step 
forward. In particular, work by Coppieters and colleagues has attempted to define 
whether the CD8+ T-cells present in inflamed human islets are antigen specific [24]. 
This critical goal has been achieved by exploiting the power of peptide-loaded, 
engineered, tetrameric antibodies (“tetramers”) which allow the selective 
identification of T-cells recognising the specific peptide in question. Using this 
approach, it was demonstrated that a proportion (currently undetermined) of the T-
cells present in inflamed islets in humans are directed against specific beta-cell 
antigens [24]. Thus, these T-cells may be homing directly to the islets, guided by the 
presentation of antigens within the islet milieu. As such, these cells may be 
responding to highly specific cues rather than simply to a generalised chemokine 
gradient existing within the vicinity of the islet.  
 
In this context, chemokines are well known to play an important role in guiding 
immune cells to sites of injury or infection and it has been surmised that the 
generation of chemokine gradients may underlie the homing of immune cells to 
inflamed islets. In support of this, a number of workers have shown that chemokines 
can be elaborated from islet cells, including molecules such as CXCL10 which may 
be important for T-cell recruitment [25,26]. However, the evidence base supporting a 
chemokine-driven recruitment mechanism in inflamed islets in human type 1 diabetes 
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remains relatively weak. Indeed, the morphology of inflamed islets in humans seems 
oddly inconsistent with such a mechanism. Thus, as discussed previously, the absolute 
numbers of immune cells that reach inflamed islets is relatively small, and it is 
difficult to understand why most immune cells appear to simply pass by if there are 
strongly chemotactic influences available to recruit them. While such observations do 
not exclude a role of chemokines, it must be acknowledged that important questions 
remain to be answered about immune cell targeting. The possibility of antigen-
specific homing certainly represents a key step in this quest. 
 
The peri-islet capsule – a brake on beta cell destruction? 
Questions surrounding the localisation and homing mechanisms employed by 
infiltrating immune cells in human islets are important and it remains unclear why the 
majority are localised around the islet periphery. A reasonable hypothesis would be to 
suggest that immune cells enter the islet vasculature from the wider circulation and 
are then subjected to homing signals (be they chemokines or other factors) which 
encourage the typical rolling adhesion as the cells transit the islet. Ultimately, strong 
adhesion and subsequent extravasation probably occur in post-capillary venules where 
shear forces are minimised. The post-capillary venules of the islet are located outside 
the peri-islet capsule [27] suggesting that extravasated immune cells may exit the 
vasculature at a point outside the islet and may then need to negotiate the capsule 
before they can gain direct access to the beta cells themselves. Important new 
advances have been made recently in understanding the components of the peri-islet 
capsule, which consists of an islet basement membrane (BM) and subjacent interstitial 
matrix (IM). The islet BM and IM enclose the islet, separating the endocrine cells 
from the surrounding exocrine acinar cells. The function of the BM is to act as a 
barrier to soluble molecules and to cells and the IM confers flexibility and elasticity 
[27-29]. The peri-islet capsule is made up of a complex mixture of extracellular 
matrix components [27-29]. Interestingly, it has been argued that immune cells cannot 
normally infiltrate the islet unless the structure of the capsule is destabilised. This may 
explain why the peri-insulitis observed frequently in the islets of type 1 diabetes 
patients (Figure 3A, Figure 5) tends to occur in those with a near normal complement 
of beta cells [18].  
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The islet BM can be digested by a variety of enzymes, such as heparanases [28] and 
cathepsins [29], which are probably released by peri-islet immune cells [28,29]. One 
could therefore hypothesise, that as the number and type of recruited immune cells 
increases around the islets, the damage inflicted on the capsule is enhanced (Figure 3: 
Focal and progressive insulitis, Figure 5) [20]. Once the peri-islet capsule has been 
sufficiently degraded, the immune cells can infiltrate and destroy the beta cells 
(Figure 3: Invasive insulitis, Figure 5). Typically islets with heavy infiltration are 
those in which the beta cells are most reduced in number. The need to penetrate the 
peri-islet BM could therefore be one reason why the destructive process takes a 
protracted period of time. Interestingly, following the complete destruction of the beta 
cells, some islets are able to reform the BM (Figure 5) suggesting that it is not the beta 
cells themselves that facilitate the production of this protective layer [29]. This may 
have importance as a clinical target in the future. If the destruction of the islet BM can 
be inhibited, the natural barrier to immune cell infiltration may prolong the survival of 
the beta cells. 
 
A role for enteroviruses in Type 1 diabetes 
As noted previously, early studies on the human type 1 diabetic pancreas provided 
indirect evidence that viral infection may play a role in disease pathogenesis. This, 
coupled with mounting epidemiological evidence, has led investigators to consider 
that direct infection of the beta cells could be driving the development of type 1 
diabetes, at least in some patients. Many different viruses, including cytomegalovirus 
(CMV), rubella, Epstein barr virus (EBV), rotavirus and in particular enteroviruses 
have been nominated as candidates [30]. Among these, the most convincing evidence 
implicates enteroviruses (single stranded, positive sense RNA viruses that belong to 
the Picornaviridae family) [31].  Over the last 25 years, a plethora of epidemiological 
studies have considered whether enteroviral infections are associated with the 
development of islet autoimmunity or the onset of clinical type 1 diabetes. A recent 
meta-analysis of 26 such studies concluded that there is a statistically significant 
association between enteroviral infection and diabetes related autoimmunity/clinical 
type 1 diabetes [31]. It was noted that the odds of having a detectable enterovirus 
infection in people with type 1 diabetes are almost 10 times greater than in unaffected 
individuals and 4 times greater in non-diabetic individuals with diabetes related 
autoantibodies [31]. Many of these studies were however, performed on peripheral 
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whole blood, preparations of PBMCs or serum samples, such that the authors also 
remarked that firm evidence of viral infection within the pancreas is still lacking [31]. 
This is in part due to the limited amount of material available for analysis. Despite, 
this the search for direct evidence of an infection within the pancreas (of those few 
cases available) began over 34 years ago…. 
 
Arguably the most convincing early evidence that enteroviruses can specifically target 
cells within the pancreas and may play a role in the development of the diabetes, came 
in the 1970s [32,7]. In these case reports, viral infection was associated with islet 
inflammation and islet cell necrosis, indicative of an acute, lytic, infection [32,7]. 
Since then a range of studies have confirmed the tropism of enteroviruses for beta 
cells both in vitro [33-35] and in vivo (particularly in fulminant type 1 diabetes, 
described in more detail below and in Tanaka et al, [36]). Importantly, this is not 
restricted to just one or two of the enterovirus family members, since Coxsackie virus 
B (CVB), Coxsackie virus A (CVA) and several of the Echoviruses are capable of 
infecting isolated human islets [33-35].  The tropism of enteroviruses for the pancreas 
was further demonstrated in vivo in a series of neonates who had died from culture 
proven Coxsackie viral myocarditis. In situ hybridisation (ISH), using a CVB-specific 
probe [37,38] confirmed the presence of CVB RNA in the heart of all cases, but 
interestingly also in the pancreas of five of the nine cases examined. The islets in 
particular were targeted while only occasional acinar cell positivity was observed 
[39,37]. 
 
These studies suggested that detection of viral RNA in the pancreas might be a viable 
means to verify whether enteroviral infection is associated with type 1 diabetes. 
However, there are a number of important issues relating to the detection of viral 
RNA in the pancreas which must be considered. Firstly, the pancreas is a particularly 
noxious environment for RNA; it is rich in RNAses, meaning that free RNA is 
susceptible to rapid degradation. Secondly, the majority of tissue studied to date have 
undergone fixation with formalin, a process which has a dramatic impact on RNA 
stability and integrity. Thirdly, the majority of samples tested so far are from 
autopsies meaning that the pancreas may have been recovered many hours after death. 
Therefore, despite the initial optimism arising from the demonstration of positive ISH 
signals in Coxsackie-proven infections, the subsequent relative failure to reproduce 
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this [37,40] in the pancreases of type 1 diabetes patients should be interpreted with 
caution.  
 
As RNA stability is an issue when examining pancreatic tissue, researchers have also 
taken an alternative approach by attempting to detect viral proteins in this tissue, since 
these are likely to be better preserved in autopsy pancreas. In the first such study [39], 
two rabbit polyclonal antibodies raised either against a fusion protein containing 
sequences from CVB3 capsid proteins (VP4, VP2 and VP3) or against the CVB3 VP1 
structural protein, were employed [41]. Both detected the presence of enterovirus in 
the heart and pancreas of confirmed Coxsackie-infected neonates, suggesting that they 
were suitable for detection of widespread, systemic, enteroviral infection in formalin-
fixed autopsy tissues [39]. In addition, these antibodies were shown to identify 
various CVBs (CVB2, CVB4 and CVB5) despite being raised against CVB3 [39].  
However, when applied to sections of autopsy pancreases from 88 patients who had 
died at, or shortly after, clinical presentation of type 1 diabetes, no positive signals 
were obtained [39]. This might be because viruses were not present in the tissue or 
alternatively it might also be because these antisera failed to bind to proteins 
expressed by the serotype of virus present. A third possibility is that the sensitivity of 
the antisera was insufficient to detect the very modest levels of protein expression 
achieved during a sub-lytic infection. Fourthly, because antigen retrieval was not in 
use at the time of this work, other technical issues might also have militated against 
virus detection.  
 
Why is it easier to find the culprit in Coxsackie-infected neonates & fulminant type 1 
diabetes? 
As hinted above, direct evidence of an enteroviral infection has been relatively easy to 
find in the pancreases of individuals presenting with an acute Coxsackie infection or 
with fulminant type 1diabetes. The latter is characterised by the acute-onset of clinical 
symptoms and differs pathologically from “classical” type 1 diabetes in that there is 
evidence of lysis of both beta and alpha cells [42,43]. Fulminant diabetes accounts for 
approximately 25% of type 1 diabetes cases in Japan, but is much rarer in European 
populations. By contrast with fulminant diabetes, in typical autoimmune type 1 
diabetes there is no evidence of cell lysis and the cell loss is selective for beta cells.  
Islet inflammation is present in both forms of diabetes, but the complement of 
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immune cells in fulminant disease differs from that observed in typical type 1 diabetes 
(reviewed in [44]). This has led some to suggest that fulminant type 1 diabetes 
represents a non-autoimmune form of the disease [45], characterised by the absence 
of diabetes-related autoantibodies, normal expression of class I MHC, lymphocytic 
infiltration of the exocrine and endocrine tissue, elevated serum pancreatic enzyme 
levels and a remarkably aggressive disease progression [45].  It appears therefore that 
the ease of identification of enterovirus in these pancreas samples may be due, in part, 
to the development of an acute lytic infection where abundant amounts of viral 
protein are present in multiple cell types.  In contrast, evidence of viral protein 
production has been much harder to find in the pancreases of patients with 
autoimmune type 1 diabetes. Why is this? 
 
In autoimmune type 1 diabetes, diabetes-related autoantibodies appear in most 
individuals years before clinical onset of the disease and the appearance of these islet 
specific autoantibodies is believed to be an indicator of a beta cell stress. 
Accumulating evidence from birth cohort studies has shown that the appearance of the 
first autoantibody correlates with evidence of an enteroviral infection in the preceding 
6 months [46,47]. This had led some to hypothesise that the initial insult to the beta 
cell is a viral infection. This might lead to secretion of interferon-alpha by beta cells 
and hyperexpression of class I MHC in infected islets, leading to the activation of 
auto-reactive cells in genetically susceptible individuals [16].  
 
Increasing the sensitivity of detection of viral proteins in the pancreas 
The development of antigen retrieval techniques (often termed “Heat Induced Epitope 
Retrieval” (HIER)) in the 1990s was game changing in the field of pathology. This 
technique allowed certain antigens that had previously been inaccessible to antibodies 
in formalin-fixed paraffin-embedded tissues, to be unmasked. HIER also allows the 
use of reduced primary antibody incubation times (and lower dilutions) such that 
staining is revealed in formalin-fixed tissues that fail to stain by conventional methods 
[48]. In summary, the application of this technique increases the sensitivity of antigen 
detection by individual antisera. A second major development in the enterovirus field 
was the production of more sensitive, broad spectrum antisera directed against 
enteroviral capsid proteins. One such antibody (clone 5D8/1) is marketed 
commercially by Dako. The antibody is monoclonal in origin, was raised against the 
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VP1 protein of Coxsackievirus B5 and has provided particularly sensitive and specific 
detection opportunities such that it has now been used extensively to detect 
enterovirus in formalin fixed tissues [49-55]. In combination, therefore, the use of 
HIER and the availability of new antisera have enabled an increase in both the 
spectrum of enteroviral serotypes which can be detected in fixed tissues and an 
improvement in the sensitivity of their detection [49-57] (and unpublished results 
Richardson et al). 
 
These important methodological advances have provided better tools for use in the 
search for enteroviral proteins in tissue from recent-onset type 1 diabetes patients. 
Accordingly, in a landmark paper published in 2007, Dotta et al reported that 
enteroviral VP1 protein was present in the islets of 2 of 5 recent-onset type 1 diabetes 
cases and in a whole pancreas graft recovered from a 26 year old recipient [23]. 
Importantly, this work revealed the presence of small numbers of intensely-stained 
endocrine cells, shown to be beta cells, within the islets. We now term these “Dotta” 
cells to recognise the importance of this contribution. The immunohistochemical 
evidence was supported by electron microscopic studies revealing the presence of 
virus particles within islet cells and by the isolation of a serotype of CVB4 (now 
referred to as the “Tuscany” isolate) from one of the cases [23]. Subsequent to this, 
we conducted a more comprehensive analysis of a cohort of recent-onset type 1 
diabetes cases collected within the UK and were able to demonstrate the presence of 
VP1+ “Dotta” cells, again proven to be beta cells,  in 44 of the 72 (61%) cases 
examined. In contrast, only 4 “Dotta” cells were identified in 3 islets from the 50 
(7.7%) neonatal and paediatric control cases examined [58]. We further demonstrated 
that HIER allowed the antiserum used in the original study that had failed to detect 
viral proteins [39], to now reveal staining in specific islets. Strikingly, these islets 
were also stained positively by clone 5D8/1 in serial sections. A further pan-
enterovirus antibody (Clone 9D5; Millipore) was also found to label individual 
endocrine cells in the islets of patients with type 1 diabetes [58]. A comparison of the 
staining patterns achieved with these three antisera in heart tissue from CVB-infected 
neonates revealed that the Dako 5D8/1 clone was both more sensitive and produced 
more consistent staining in the face of a variety of different fixatives when compared 
to the other two [58,57] (and unpublished results Richardson et al). Hence, when 
considered together, these studies provided the first firm evidence that enteroviral 
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infection, confined to beta cells, can be detected in the islet cells of a significant 
number of people with a recent diagnosis of type 1 diabetes.  
 
The UK cohort used in our work represents the largest single collection of recent-
onset type 1 diabetes pancreases in the world and has proved invaluable as a means to 
study the underlying pathology of this illness. However, despite this there are several 
limitations (notably the historical nature of the collection; its specific geographical 
location and the non-uniform fixation methods employed). To address these, we have 
recently had the opportunity to examine a second cohort of pancreases from patients 
with type 1 diabetes, collected under the auspices of the Juvenile Diabetes Research 
Foundation’s network of Pancreatic Organ Donors (nPOD) with Diabetes programme 
(http://www.jdrfnpod.org/index.php) [59]. This important and growing resource 
promises much, since it should facilitate future collaborative studies to better 
understand the pathogenesis of type 1 diabetes. However, the number of recent-onset 
cases (<1 year) in this collection is still very small. Indeed, initially we were only able 
to access 1 case of short clinical duration among 10 cases which retained insulin-
containing islets[60]. We also examined a further 7 cases in which only insulin-
deficient islets were present. Importantly, the mean time since diagnosis in the 17 type 
1 diabetes cases studied was 11.9±2.3 years; which compared to only 8.2±4.1 months 
(i.e. 0.68 years) in the UK cohort. However, despite this, we noted that many of the 
pathological features highlighted in the UK cohort could still be observed in the 
American cases. We were therefore intrigued to investigate whether islet enteroviral 
infection could be detected in this cohort.  
 
In short, the firm answer to this question is “yes”. In 8 of the 10 cases where residual 
beta cells were present, intensely stained VP1+ (“Dotta”) cells were seen [60]. By 
contrast, no evidence of staining was observed in the 7 cases with only insulin-
deficient islets. Serial sections of a representative islet from an nPOD case are shown 
in Fig2 demonstrating VP1 expression in an insulin-containing islet with hyper 
expression of class I MHC.  Importantly, VP1+ cells were seen in only 1 of 12 age-
matched non-diabetic controls [60].  Within this (and the UK) cohort, it is important 
to emphasise the absolute numbers of VP1+ cells within any given patient is 
vanishingly small.  Indeed, even in those cases with the highest proportion of “Dotta” 
cells, we calculate that less than 0.005-0.01% of the cells within the entire pancreas 
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section stain positively for VP1 suggesting that viral infection of beta-cells does not 
proceed with a typical, acute, lytic course.  
 
One further consideration is important since it has been proposed that clone 5D8/1 
can, under certain conditions, cross-react with two additional proteins in the pancreas, 
creatine kinase B (CKB) and ATP5B [61]. To address this issue, we have examined 
this cross-reactivity in greater detail and show that, under optimised conditions, the 
immunostaining achieved with clone 5D8/1 in formalin-fixed paraffin embedded 
tissue or cells, retains its specificity for VP1 [62].  
 
Additional support for the hypothesis that the VP1 staining of the beta cells in the 
islets of type 1 diabetes patients represents a bona fide infection is the finding that the 
pathogen recognition receptor, protein kinase R (PKR) is selectively up-regulated in 
VP1+ islet cells. This has been confirmed in both the UK and nPOD cohorts [60]. It 
has been shown by others that PKR is both induced and activated following an 
enteroviral infection and that this leads to phosphorylation of an elongation factor, 
eIF2alpha, involved in protein synthesis [63,64]. This causes translational arrest and, 
as such, will result in the selective depletion of the more labile proteins. Therefore, we 
took advantage of this situation to study the expression of a labile, anti-apoptotic 
protein, Mcl-1, in VP1+ (PKR+) islet cells. Mcl-1 is constitutively expressed at high 
levels in most beta cells [60] and from in vitro studies, the protein is understood to be 
a critical determinant of beta cell fate in response to stressors (such as pro-
inflammatory cytokines and viral infection) [65]. Importantly, we observed that Mcl-1 
was selectively depleted from beta-cells expressing VP1 and PKR suggesting that 
these individual cells might then be rendered more sensitive to the detrimental effects 
of the pro-inflammatory mileu existing within inflamed islets [60].  
 
Is islet VP1 immunopositivity the tip of an iceberg? 
The presence of interferon-alpha within most residual beta cells patients at clinical 
onset of type 1 diabetes contrasts with the relative scarcity of “Dotta” cells expressing 
enteroviral VP1 protein. How can this be explained? In an acute lytic enteroviral 
infection the positive strand RNA of the virus is transcribed within the infected cell to 
produce a negative strand RNA template. This in turn is transcribed to produce 
hundreds of copies of positive strand RNA viral molecules which are then translated, 
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with synthesis of complete viral particles. Upon reaching a critical mass of these 
particles the cells bursts and releases virus.  By contrast, in a chronic non-lytic 
enteroviral infection there are equal numbers of positive and negative viral RNA 
molecules and there is little synthesis of complete viral particles expressing viral 
capsid proteins [66-68]. Thus the “Dotta” cells seen in type 1 diabetes may represent 
the ‘tip of the iceberg’ of viral infection within the islet. The beta cells synthesizing 
interferon-alpha may well be chronically infected by enterovirus existing, not as 
complete viral particles, but as double stranded RNA, a well-recognised stimulant of 
interferon synthesis (reviewed in [69]). In our study [58], we found that among young 
children, enteroviral infection of beta cells was much more frequent in patients with 
type 1 diabetes than those without. However, we suspect that it is not just the presence 
or absence of virus per se within a beta cell which is of most significance for the onset 
of diabetes. Rather, it may be the response of the cell to an on-going viral infection 
that matters. Conceivably, it is those children who respond most vigorously to an 
early beta-cell enteroviral infection, by mounting a strong interferon response, who 
are at greatest risk of triggering islet autoimmunity. Interferon secretion will cause 
hyper expression of class I MHC within the islet endocrine cells, which in turn 
probably initiates insulitis. Those children who respond minimally (or not at all) to an 
enteroviral infection of beta cells may be relatively protected from developing islet 
autoimmunity. 
 
Are the beta cells trying to fight back? 
Studies in the UK recent-onset paediatric cohort of type 1 diabetes patients have 
provided evidence that endocrine cells (both beta and alpha) display a 10-fold 
increase in proliferation when compared to controls [70]. This was strongly associated 
with the presence of insulitis suggesting that factors released from the immune cells 
could be driving an attempt by the beta cells to increase their numbers in the face of 
the attack [70]. The presence of proliferating endocrine cells was also frequently 
observed in islets with VP1 staining, implying that a viral infection could be inducing 
the recruitment of the immune cells, which in turn release factors that promote 
endocrine cell proliferation [71]. The finding that endocrine cell proliferation was 
increased in some islet autoantibody positive organ donors with evidence of insulitis 
[72] and that proliferation was not observed in adult, longer duration type 1 diabetes 
patients [73] who rarely have evidence of insulitis, lends support to this hypothesis. 
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Proposed sequence of events - 2014 
In individuals at-risk of developing type 1 diabetes, a non-cytopathic chronic viral 
infection of pancreatic beta cells is sensed by host pathogen recognition receptors. 
Activation of these receptors induces the expression of interferon-alpha (as part of an 
innate immune response to the double stranded RNA of the virus) which results in 
hyper-expression of class I MHC by the endocrine cells of the islet and release of 
factors that promote the recruitment of immune cells. However the islet has a 
protective basement membrane that can prevent direct contact between the immune 
cells and the beta cells. As the recruitment of more immune cells to the affected islets 
occurs a slow progression of insulitic destruction may occur (demonstrated by peri-
insulitis, focal insulitis, progressive insulitis and finally invasive insulitis), invasive 
insulitis occurring once the basement membrane has been sufficiently degraded by 
enzymes released by the infiltrating cells. At this point the invasive immune cells 
actively target and kill the beta cells leading to the formation of insulin-deficient 
islets, where under certain circumstances the basement membrane can reform. This 
progressive destruction of islets (over years) leads to the development of clinical 
diabetes (Fig5). 
 
Summary 
We have come a long way in 25 years - but we still have a very long way to go. Many 
questions remain unanswered and the limited amount and type of material available in 
which to address these questions restricts the speed at which they can be answered. 
However, the establishment of large international collaborative networks such as 
nPOD and EU Framework 7 funded PEVNET (Persistent virus infection as a cause of 
pathogenic inflammation in type 1 diabetes – an innovative research program of 
biobanks and expertise) are enabling expert researchers to combine their skills, 
question hypothesises and push forward our knowledge in this area. In particular the 
nPOD (organ donor pancreases) and the Norwegian DiViD (distal pancreatectomy 
specimens in patients with recent onset type 1 diabetes)  collections are likely to prove 
critical to finally answering the virus question as these tissues are optimally 
preserved, can be used to perform islet dissection and are suitable for next-generation 
sequencing analysis. We are sure that the next 25 years will prove to be even more 
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fruitful than the last, as this collective effort really starts to help us understand the 
changes that beset the pancreas of type 1 diabetes patients.  
 
Twenty-five years ago findings in the diabetic pancreas suggested that both 
hypotheses raised by Gepts might be right:  viral infection of islet beta cells might 
lead to a destructive autoimmune response directed against them. Twenty-five years 
further on we still think he is right! 
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FIGURE LEGENDS 
 
Fig1: The lobular nature of type 1 diabetes. A photomicrograph of a pancreas from a 
type 1 diabetes patient (from the nPOD collection) stained via immunohistochemistry 
for the presence of glucagon (A) and a serial section stained for insulin (B). The lobe 
containing ICIs can be seen on the right (hashed line), whereas the neighbouring lobe 
contains only IDIs. 
 
Fig2: A photomicrograph of a non-diabetic control (A-C) and a type 1 diabetes patient 
(D-F) immunostained for insulin (red) and glucagon (brown – A and D), class I MHC 
(B and E) and enteroviral VP1 (C and F). 
 
Fig3: The proposed sequence of events in islets in type 1 diabetes 25 years ago (Alan 
Foulis, Pathology Society 1987 Oakley Lecture). 
 
Fig4: Insulitic lesions in type 1 diabetes. Representative islets from nPOD cases 
immunostained for insulin (blue), the Pan lymphotcyte marker CD45 (green) and 
TOPRO (Red) demonstrating the proposed progression of the insulitic lesion. A. Peri-
insulitis, B. Focal insulitis, C. Progressive insulitis and D. Invasive insulitis.  
 
Fig 5: Proposed sequence of events in type 1 diabetes – 2014.  
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Fig1: Lobular loss of insulin-containing islets 
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Fig2: Hyper expression of Class I MHC in type 1 diabetes 
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Fig4: Heterogeneity of insulitis; is it related to the stage of destruction (peri-islet, polar, progressive and invasive)? 
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